Abstract
Uterine sarcomas comprise endometrial stroma tumors (EST) and uterine leiomyosarcomas (ULMS), with ESTs accounting for less than 2% and ULMS accounting for approximately 1% of uterine neoplasms. Recent classifications of ESTs denote as many as four categories: benign endometrial stromal nodule (ESN), low-grade endometrial stromal sarcomas (ESS), high-grade endometrial stromal sarcomas (HGESS), and undifferentiated uterine sarcomas (UUS). The designation UUS has been suggested to encompass undifferentiated endometrial sarcomas (UES) and undifferentiated uterine sarcomas of other tissue origins. The prognosis for ESS is good. Although a third of cases recur, the 5-year survival rate for Stage I disease can be as high as 98%. In contrast the prognosis for UES is poor, with a 5-year survival rate for Stage I disease at 57%. Few patients with UES survive two years. ULMS represents the most common single type of uterine sarcoma and is associated with a poor prognosis. Recurrence rates are estimated at 50-70% and the 5-year survival rate for Stage I approximates 51%. The authors present a review of these tumors from the vantage point of clinical work up and diagnosis, treatment options, and adjuvant therapy including hormonal therapy, radiation therapy, and chemotherapy. Included are accounts of pertinent phase II and III clinical trials. The article concludes with commentary on future treatment directions for these rare tumors.
Keywords: Stromal, sarcoma, leiomyosarcoma, undifferentiated, TP53, JAZF1/SUZ12, YWHAEFAM22, hormone, chemotherapy, pazopanib.
Current Cancer Therapy Reviews
Title:Current Strategies and Future Directions in Classification and Treatment of Uterine Sarcomas
Volume: 11 Issue: 4
Author(s): Mary Chu, D. Stave Kohtz, Estrelania Williams, Tamara Kalir and David Fishman
Affiliation:
Keywords: Stromal, sarcoma, leiomyosarcoma, undifferentiated, TP53, JAZF1/SUZ12, YWHAEFAM22, hormone, chemotherapy, pazopanib.
Abstract: Uterine sarcomas comprise endometrial stroma tumors (EST) and uterine leiomyosarcomas (ULMS), with ESTs accounting for less than 2% and ULMS accounting for approximately 1% of uterine neoplasms. Recent classifications of ESTs denote as many as four categories: benign endometrial stromal nodule (ESN), low-grade endometrial stromal sarcomas (ESS), high-grade endometrial stromal sarcomas (HGESS), and undifferentiated uterine sarcomas (UUS). The designation UUS has been suggested to encompass undifferentiated endometrial sarcomas (UES) and undifferentiated uterine sarcomas of other tissue origins. The prognosis for ESS is good. Although a third of cases recur, the 5-year survival rate for Stage I disease can be as high as 98%. In contrast the prognosis for UES is poor, with a 5-year survival rate for Stage I disease at 57%. Few patients with UES survive two years. ULMS represents the most common single type of uterine sarcoma and is associated with a poor prognosis. Recurrence rates are estimated at 50-70% and the 5-year survival rate for Stage I approximates 51%. The authors present a review of these tumors from the vantage point of clinical work up and diagnosis, treatment options, and adjuvant therapy including hormonal therapy, radiation therapy, and chemotherapy. Included are accounts of pertinent phase II and III clinical trials. The article concludes with commentary on future treatment directions for these rare tumors.
Export Options
About this article
Cite this article as:
Chu Mary, Stave Kohtz D., Williams Estrelania, Kalir Tamara and Fishman David, Current Strategies and Future Directions in Classification and Treatment of Uterine Sarcomas, Current Cancer Therapy Reviews 2015; 11 (4) . https://dx.doi.org/10.2174/1573394712666151119214053
DOI https://dx.doi.org/10.2174/1573394712666151119214053 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Animal Mitochondria: Evolution, Function, and Disease
Current Molecular Medicine Neuroblastoma and Stem Cell Therapy: An Updated Review
CNS & Neurological Disorders - Drug Targets The Role of Neurotrophins in Axonal Growth, Guidance, and Regeneration
Current Neurovascular Research The Role of Cytochrome P450 in Cytotoxic Bioactivation: Future Therapeutic Directions
Current Cancer Drug Targets Cisplatin Analogues with an Increased Interaction with DNA: Prospects for Therapy
Current Pharmaceutical Design Synthesis and Application of Stable Nitroxide Free Radicals Fused with Carbocycles and Heterocycles
Current Organic Chemistry Exploiting EPR in Polymer Drug Conjugate Delivery for Tumor Targeting
Current Pharmaceutical Design Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease
Current Drug Delivery Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research Response to HAART in Treatment-Naive HIV-Infected Patients with a Prior Diagnosis of Tuberculosis or other Opportunistic Infections
Current HIV Research Enantioselective Organocatalytic Reactions with Isatin
Current Organic Chemistry Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics
Current Medicinal Chemistry Crocins: The Active Constituents of Crocus Sativus L. Stigmas, Exert Significant Cytotoxicity on Tumor Cells In Vitro
Current Cancer Therapy Reviews Royal Jelly Acid, 10-Hydroxy-trans-2-Decenoic Acid, as a Modulator of the Innate Immune Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets Nuclear Magnetic Resonance Spectroscopy of Lipids in Cancer
Current Organic Chemistry Using a Hybrid Radioenhancer to Discover Tumor Cell-targeted Treatment for Osteosarcoma: An In Vitro Study
Current Medicinal Chemistry Strategies for Effective Naked-DNA Vaccination Against Infectious Diseases
Recent Patents on Anti-Infective Drug Discovery Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
Current Cancer Drug Targets The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy
Current Drug Metabolism Strategies for Increasing the Solubility and Bioavailability of Anticancer Compounds: β-Lapachone and Other Naphthoquinones
Current Pharmaceutical Design